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OBJECTIVE: Prader-Willi Syndrome is a common etiology of syndromic obesity that is typically caused by either a
paternal microdeletion of a region in chromosome 15 (microdeletions) or a maternal uniparental disomy of this
chromosome. The purpose of this study was to describe the most significant clinical features of 35 Brazilian patients
with molecularly confirmed Prader-Willi syndrome and to determine the effects of growth hormone treatment on
clinical outcomes.
METHODS: A retrospective study was performed based on the medical records of a cohort of 35 patients diagnosed
with Prader-Willi syndrome. The main clinical characteristics were compared between the group of patients
presenting with microdeletions and the group presenting with maternal uniparental disomy of chromosome 15.
Curves for height/length, weight and body mass index were constructed and compared between Prader-Willi
syndrome patients treated with and without growth hormone to determine how growth hormone treatment
affected body composition. The curves for these patient groups were also compared with curves for the normal
population.
RESULTS: No significant differences were identified between patients with microdeletions and patients with
maternal uniparental disomy for any of the clinical parameters measured. Growth hormone treatment considerably
improved the control of weight gain and body mass index for female patients but had no effect on either parameter
in male patients. Growth hormone treatment did not affect height/length in either gender.
CONCLUSION: The prevalence rates of several clinical features in this study are in agreement with the rates reported
in the literature. Additionally, we found modest benefits of growth hormone treatment but failed to demonstrate
differences between patients with microdeletions and those with maternal uniparental disomy. The control of
weight gain in patients with Prader-Willi syndrome is complex and does not depend exclusively on growth hormone
treatment.
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INTRODUCTION
One of the most common causes of syndromic obesity is
Prader-Willi syndrome (PWS), which has a peculiar evolu-
tion that is characterized by childhood-onset obesity, facial
dysmorphisms, hypogonadism, short stature, intellectual
handicap and an insatiable appetite, leading to signifi-
cant clinical complications later in life. Interestingly, these
symptoms are preceded by marked neonatal hypotonia, a
poor suck reflex and a failure to thrive beginning at birth
that typically improves within the first year of life (1-10).
The underlying genetic cause of this pleiotropic disorder
is the lack of expression of paternal genes in the critical
chromosome region 15q11-13. This lack of expression is due
to a de novo paternal microdeletion of this region in 75%
of cases (microdeletions), a maternal uniparental disomy
(mUPD) of chromosome 15 in 20% of cases and either struc-
tural chromosomal aberrations or imprinting center defects
in roughly 5% of cases (1-13).
The most important complications of PWS are related to
the cardiovascular and respiratory involvement caused by
obesity. These complications are directly responsible for the
high incidence of death among children and adults with
PWS, close to 3% per year (2-4). However, the literature
lacks comprehensive information on the long-term survival
of PWS patients.
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There is no specific treatment for PWS. The clinical follow-
up is based on constant surveillance and the treatment of
common complications. In addition, growth hormone repla-
cement therapy (GHt) is often used to improve final stature
and to control weight gain (1,9,10).
The purpose of this study was to describe the most
significant clinical features during a long-term follow-up
of 35 Brazilian patients with molecularly confirmed
PWS and to determine the effects of GHt on the clinical
outcomes.
METHODS
A retrospective study was performed based on the
medical records of a cohort of 35 patients (18 males and 17
females) diagnosed with PWS and followed in our service.
Twenty-three patients had undergone regular follow-up
visits in our service, six patients had incomplete clinical in-
formation, and six patients died from complications related
to PWS.
All subjects included in this study had a typical DNA
methylation pattern of the PWS critical region. The DNA
was modified by bisulfite treatment, and SNURF-SNRPN
exon 1 was amplified by PCR (14). The characteristic PWS
pattern is defined by the presence of only the 313 bp
maternal band. Three microsatellite markers within the
critical region of 15q11-q13 (D15S11, D15S113 and GABRB3)
and at least one marker outside this region (D15S984,
D15S131, D15S117, D15S115 and CYP19) were studied in 24
patients and their parents to distinguish between deletions
and maternal uniparental disomy; 16 patients had micro-
deletions (eleven males and five females), and eight had
mUPD (two males and six females). All patients presented
with normal peripheral blood karyotypes. In 11 cases (five
males and six females), molecular tests to differentiate
between mUPD and microdeletions were not performed.
The clinical features for which the data were not normally
distributed were compared between the mUPD and micro-
deletion groups using Fisher’s exact test. Variables with
normal distributions, including weight, BMI and height,
were compared with Student’s t test.
To determine how GHt affected body composition, curves
for height/length, weight and body mass index (BMI) were
visually compared between PWS patients treated with and
without GHt. These growth curves were also compared
with the reference growth charts for normal populations
from the World Health Organization and the National
Center for Health Statistics (WHO/NCHS; referred to as the
normal population curve).
The means and standard deviations (SDs) of all ages
(from 0 to 19 y; calculated using the mean of each individual
for each age) were adjusted using the distance-weighted
least squares method to calculate the growth curves (Lam,
1983; McLain, 1974) for our patents and for the normal
population. Each patient contributed between 1 and 22
measurements at different ages, ranging from birth to 23 y 5
mo. Graphical and statistical analyses were performed using
STATISTICA 7.0 and Microsoft Excel.
RESULTS
The most relevant clinical features of our cohort of PWS
patients and the comparisons between patients with
microdeletions and mUPD are summarized in Table 1.
Some of the main clinical findings in our cohort were as
follows: preterm birth (3%), birth by Cesarean section (90%),
hypotonia (100%), poor suck reflex and feeding problems
(92%), developmental delay (97%), cryptorchidism in males
(43%) and hypogonadism (57%).
The birth weight ranged from 1,020 g to 3,650 g (mean:
2,717 g), and the birth length ranged from 34.5 cm to
54.0 cm (mean: 47.7 cm). The mean age at walking was 2.4
years (range: 1.2 y-4.5 y). Hyperphagia presented between 1
y and 5 y (mean: 2.8 y) of age, and obesity developed
between 1 y and 6 y (mean: 2.6 y) of age.
GHt was started in 11 patients (eight male and three
female patients) between 1.2 y and 11.5 y (mean: 6.5 y) of
age, with the length of therapy varying from 0.5 y to 6.6 y
(mean: 3.8 y).
No significant differences were found when comparing
the clinical parameters between patients with microdele-
tions and those with mUPD.
Table 1 - The distribution of relevant clinical features in individuals with Prader-Willi syndrome. The columns ‘‘mUPD’’
and ‘‘microdeletion’’ show the numbers of patients with each feature in the maternal uniparental disomy of
chromosome 15 and microdeletion groups, respectively. The numerator shows the absolute value, and the denominator
represents the number of individuals in whom the feature was evaluated. The column ‘‘Total’’ shows the data for all 35
patients with Prader-Willi syndrome. Note that the row ‘‘Age’’ presented the mean age and the corresponding standard
deviation for each group.
Clinical Features mUPD (n=8) Microdeletion (n= 16) Total (n = 35)
Gender: female 6/8 5/16 17/35
male 2/8 11/16 18/35
Age: mean (SD) 12.2 y (5.9 y) 12.9 y (4.6 y) 13.7 y (6.9 y)
Assisted delivery 8/8 13/13 25/26
Hypotonia 8/8 14/14 32/32
Feeding problems 6/7 10/11 24/26
Developmental delay 8/8 14/14 30/31
Facial dysmorphisms 8/8 10/10 24/24
Hypogonadism 3/7 9/13 12/27
Cryptorchidism 2/7 7/13 15/30
Sleep disturbances 4/5 3/4 12/14
Death 1/8 3/14 4/35
Patients diagnosed before 4 y.o. 4/8 8/15 17/31
Use of growth hormone therapy 4/8 5/14 13/32
Follow-up of Prader-Willi syndrome patients
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Six patients died between 1.5 y and 19 y (mean: 11.6 y) of
age. The cause of death was determined in four cases; three
patients died due to cardiovascular/respiratory complica-
tions from obesity, and one died from endocarditis at 1.5 y of
age. In the two other cases, no autopsy was performed, and
the cause of death was not determined. Of the six deceased
patients, three had microdeletions, one had mUPD, and in
the remaining two, themolecular test to determine the genetic
mechanism of deletion was not performed. Comparing the
death rate between the mUPD and microdeletion groups
showed no significant difference (p,0.05).
The weight, BMI and length/height curves for PWS
patients were compared with the WHO/NCHS curves for
the normal population (Figure 1).
Weight/BMI curves
Males: The use of GHt in males did not decrease weight
gain. The mean weight for PWS patients treated with growth
hormone exceeded +2 SDs of the mean weight of the normal
population by age 4, and the mean weight of PWS patients not
treated with growth hormone exceeded 2 SDs of the normal
meanweight by the age of 7. Thereafter, both remained groups
above +2 SDs compared with the WHO/NCHS curve for the
normal population. When comparing the BMI curves of male
patients with or without GHt, both groups started below -2
SDs and later exceeded +2 SDs of the WHO/NCHS curve for
the normal population during infancy. This increase in BMI
occurred earlier in patients previously treated with growth
hormone, reflecting rapid weight gain and the inability of the
length/height increase to counterbalance the weight gain.
Females: Female patients treated with growth hormone
showed improvement in weight gain. Female patients treated
with growth hormone had a weight curve that remained close
to themean of the normal population, whereas female patients
not treated with growth hormone had a curve that exceeded
+2 SDs by the age of four, with a continuing upward trend.
When comparing BMI curves, a similar trend was observed.
Female patients previously treated with growth hormone
remained between the mean and +2 SDs of the normal
population, whereas female patients not treated with growth
hormone exceeded +2 SDs at the age of two and continued a
rapid upward trend.
Length/Height
Males: When comparing the length/height curves for
male patients, we observed that patients who received GHt
started below -2 SDs in the WHO/NCHS curve of normal
children and, by the age of six, were closer to the mean,
whereas those without GHt fell below the -2 SD curve.
Despite these early differences, when male patients with or
without GHt reached eighteen years old, the curves crossed
at a point close to -2 SDs.
Females: When analyzing the length/height curves for
female patients, female patients without GHt started below -
2 SDs and, by the age of six, approached the mean of the
WHO/NCHS curve of the normal population and stayed at
the same level until the age of 15, when a negative slope was
noted. The GHt group always remained below -2 SDs.
DISCUSSION
We have presented the most relevant clinical features of a
large case series of Prader-Willi syndrome patients in Brazil.
Several findings in our retrospective analysis are consistent
with the results published in the literature, such as the
frequencies of microdeletion/mUPD, hypotonia, facial dys-
morphisms, developmental milestone delays, feeding diffi-
culties, hypogonadism and cryptorchidism (1,11,12).
Clinical findings
Hypotonia was present in the first year of life for all
patients, leading to feeding problems in the great majority of
patients. In this study, only six patients were diagnosed with
PWS before 12 months of age. This low number of early
diagnoses reflects the difficulty in correctly diagnosing PWS
and the lack of proper diagnostic methods available to the
public health system in Brazil. The late diagnoses may have
skewed our results. Interestingly, we observed that hyper-
phagia onset and the time of PWS diagnosis were positively
correlated. The presence of severe hypotonia or significant
feeding problems should indicate the possibility of PWS and
warrants genetic testing to confirm the diagnosis.
Obesity and hyperphagia began early in life. This
observation suggests that the pathophysiology of obesity
in PWS is complex and is not only related to high caloric
intake but also to hypothalamic and hormonal dysregula-
tion and low energy expenditure (5,6).
Our study showed a tendency for children with PWS to
have birth lengths and weights below the -2 SD curve for the
normal population. Children with PWS then exhibit an
increase in weight at approximately two years of age, when
they exceed the +2 SD curve. The height curve also showed
an increase, but this increase was modest and not sufficient
to pull the patients above the -2 SD curve for height. These
results are concordant to those in the literature (1,13).
The mortality rate (17%) observed in our study was high
for a young population. It is remarkable that all six patients
died prematurely before adulthood (mean age: 11.6 y).
Microdeletions and mUPD
We did not find significant differences in any of the other
clinical parameters measured between patients with micro-
deletions and mUPD. We believe that our sample, though
considerable for a genetic disorder, was not large enough to
reach statistical significance.
Growth hormone replacement therapy
In our study, GHt considerably improved the control of
weight gain and the BMI for female patients but not for male
patients. GHt did not improve height/length in either
gender. The control of weight gain in patients with PWS is
complex and does not depend exclusively on GHt; other
factors, such as food-intake control, exercise and active
participation from the family, were not addressed and may
have overcome the benefits of GHt in male patients (1,8).
The benefits of GHt in individuals with PWS have been
demonstrated in multiple studies. GHt improves linear growth
velocity and ultimate height, body composition (i.e., increased
lean body mass and decreased fat mass), muscle function and
the level of activity (9,10). However, in the present study, there
was a large heterogeneity among patients receiving GHt, and
the variability in the length of treatment may have directly
influenced the efficacy of GHt, especially for the male patients.
Furthermore, there may have been a selection bias because
fewer data were available for older patients.
The treatment of PWS patients involves identifying and
managing symptoms. A multidisciplinary approach, includ-
ing controlling food access, hormone replacement therapies,
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special education, and psychological follow-up, is crucial
for the successful management of the disease (1).
We presented our observations from a clinical follow-up of
a large cohort of Brazilian PWS patients to raise awareness in
the medical community about PWS as an important cause
of syndromic obesity and to characterize the most serious
clinical outcomes in Brazil. We observed a high mortality rate
in a young population. Moreover, GHt did not improve the
Figure 1 -Weight, BMI and length/height curves for PWS patients compared with the WHO/NCHS curve for the normal population. The
‘‘Normal’’ curve represents the mean of the WHO/NCHS curve for the normal population; ‘‘+2SD’’ and ‘‘-2SD’’ represent, respectively,
two standard deviations above and two standard deviations below the mean of the normal population. The ‘‘GHt+’’ curve represents
the mean of the patients who received at least six months of growth hormone treatment, and ‘‘GHt-’’ represents the mean of the
patients who did not undergo growth hormone treatment.
Follow-up of Prader-Willi syndrome patients
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control of the majority of the clinical parameters that were
analyzed, demonstrating that the control of weight gain in
patients with PWS is complex and does not depend exclu-
sively on GHt.
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